219
{"meta":"{\"title\":\"The Swiss Center for Musculoskeletal Biobanking is participating in the Joint Health sub-study of the MOTIVATE clinical trial.\",\"subtitle\":\"The Swiss Center for Musculoskeletal Biobanking is participating in the Joint Health sub-study of the MOTIVATE clinical trial.\",\"abstract\":\"\",\"description\":\"The trial aims to capture different approaches to the treatment and management of people with haemophilia A who develop inhibitors to treatment with the blood coagulation protein Factor VIII.\",\"keywords\":\"\",\"canonical\":\"\",\"robots\":{\"noIndex\":false,\"noFollow\":false},\"author\":\"\",\"authorEmail\":\"\",\"ogTitle\":\"MOTIVATE \\u2013 Modern Treatment of Inhibitor Patients\",\"ogDescription\":\"The trial aims to capture different approaches to the treatment and management of people with haemophilia A who develop inhibitors to treatment with the blood coagulation protein Factor VIII.\",\"twitterTitle\":\"MOTIVATE \\u2013 Modern Treatment of Inhibitor Patients\",\"twitterDescription\":\"The trial aims to capture different approaches to the treatment and management of people with haemophilia A who develop inhibitors to treatment with the blood coagulation protein Factor VIII.\",\"twitterCard\":\"summary\",\"ogImage\":\"\",\"twitterImage\":\"\"}","data":"{\"id\":219,\"type\":\"Standard\",\"slug\":\"\\\/reports\\\/success-stories\\\/motivate-modern-treatment-of-inhibitor-patients\",\"media\":[],\"categories\":\"\",\"breadcrumbs\":[{\"title\":\"Balgrist Campus\",\"link\":\"\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Facts, Figures & Visuals\",\"link\":\"\\\/facts-figures\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Publications & Reports\",\"link\":\"\\\/reports\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"Success Stories\",\"link\":\"\\\/reports\\\/success-stories\\\/\",\"target\":\"\",\"active\":1,\"current\":0,\"spacer\":0,\"hasSubpages\":1},{\"title\":\"MOTIVATE \\u2013 Modern Treatment of Inhibitor Patients\",\"link\":\"\\\/reports\\\/success-stories\\\/motivate-modern-treatment-of-inhibitor-patients\\\/\",\"target\":\"\",\"active\":1,\"current\":1,\"spacer\":0,\"hasSubpages\":0}],\"appearance\":{\"layout\":\"layout-0\",\"backendLayout\":\"default\"}}"}
Publications & Reports >
Success Stories >
MOTIVATE – Modern Treatment of Inhibitor Patients
MOTIVATE – Modern Treatment of Inhibitor Patients
The Swiss Center for Musculoskeletal Biobanking is participating in the Joint Health sub-study of the MOTIVATE clinical trial.
The trial aims to capture different approaches to the treatment and management of people with haemophilia A who develop inhibitors to treatment with the blood coagulation protein Factor VIII.
For people with haemophilia A, factor VIII (FVIII) replacement therapy is used to prevent and treat bleeding. The most serious complication of FVIII replacement therapy is the development of inhibitors against FVIII. Inhibitors prevent FVIII concentrate from controlling bleeding. As a result, people with inhibitors have increased risk of bleeding and joint problems, poorer quality of life and higher treatment costs. MOTIVATE (MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A) is studying different approaches to treating people with inhibitors, to better understand how best to care for these patients.
Due to recurrent bleedings, haemophilia A patients often experience joint damage at a much earlier age as compared to the normal population. Next to its role in coagulation, FVIII may also play a direct role in controlling inflammation and preserving bone mineral density and joint health, and the presence of FVIII inhibitors may decrease the ability for FVIII to exert these additional functions.
Therefore, as part of MOTIVATE, the sub-study Joint Health will evaluate the impact of different treatment approaches on levels of established bone and joint health biomarkers, and also aims to identify and validate new markers of early-onset joint degeneration.
"The SCMB is helping us to reach our goals in the Joint Health sub-study of MOTIVATE; we are happy to have them in our team."
Dr. med. Carmen Escuriola-Ettingshausen; Director of the HZRM Haemophilia Centre Rhine Main, Mörfelden-Walldorf, Germany
More information can be found at:
www.motivate-study.com
ClinicalTrials.gov Identifier: NCT04023019
EudraCT Number: 2019-003427-38
The trial is led by Dr. Carmen Escuriola-Ettingshausen, Director of the HZRM Hämophilie-Zentrum Rhein Main (Mörfelden-Walldorf, Germany) and Dr. Robert Sidonio Jr., Director of Clinical Operations Hemophilia of the Georgia Center for Bleeding & Clotting Disorders, Children’s Healthcare of Atlanta (Atlanta, GA, USA).